XADAGO Drug Patent Profile

When do Xadago patents expire, and when can generic versions of Xadago launch?

Xadago is a drug marketed by Mdd Us and is included in one NDA. There are three patents protecting this drug.

This drug has ninety-seven patent family members in thirty-one countries.

The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the safinamide mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xadago

A generic version of XADAGO was approved as safinamide mesylate by PRINSTON INC on April 25^th, 2024.

Summary for XADAGO

International Patents:	97
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	5
Patent Applications:	1,258
Drug Prices:	Drug price information for XADAGO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XADAGO
What excipients (inactive ingredients) are in XADAGO?	XADAGO excipients list
DailyMed Link:	XADAGO at DailyMed

See drug prices for XADAGO

Recent Clinical Trials for XADAGO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zambon SpA	Phase 2
Alain Kaelin	Phase 4
Clinical Trial Unit Ente Ospedaliero Cantonale	Phase 4

See all XADAGO clinical trials

Pharmacology for XADAGO

Drug Class	Monoamine Oxidase Type B Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Monoamine Oxidase-B Inhibitors

US Patents and Regulatory Information for XADAGO

XADAGO is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-001	Mar 21, 2017	AB	RX	Yes	No			Y	Y
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-002	Mar 21, 2017	AB	RX	Yes	Yes				Y
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-001	Mar 21, 2017	AB	RX	Yes	No				Y
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-001	Mar 21, 2017	AB	RX	Yes	No
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-002	Mar 21, 2017	AB	RX	Yes	Yes			Y	Y
Mdd Us	XADAGO	safinamide mesylate	TABLET;ORAL	207145-002	Mar 21, 2017	AB	RX	Yes	Yes

International Patents for XADAGO

When does loss-of-exclusivity occur for XADAGO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Norway

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XADAGO around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	20090231
Israel	216403	הרכב רוקחי בתצורה משולבת המכיל סאלפינאמיד ואגוניסט דופמין ושימוש בו (Pharmaceutical composition in combined form comprising salfinamide and a dopamine agonist and uses thereof)
Eurasian Patent Organization	200970028
Slovenia	2474521
Norway	342644
Denmark	2029524

Supplementary Protection Certificates for XADAGO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1613296	122015000058	Germany		PRODUCT NAME: XADAGO; REGISTRATION NO/DATE: EU/1/14/984 20150224
1613296	CA 2015 00042	Denmark		PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224
1613296	C20150033 00258	Estonia		PRODUCT NAME: SAFINAMIID;REG NO/DATE: EU/1/14/984 26.02.2015
1613296	C 2015 034	Romania		PRODUCT NAME: SAFINAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/14/984; DATE OF NATIONAL AUTHORISATION: 20150224; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/984; DATE OF FIRST AUTHORISATION IN EEA: 20150224
1613296	241 50017-2015	Slovakia		PRODUCT NAME: SAFINAMID; REGISTRATION NO/DATE: EU/1/14/984/001 - EU/1/14/984/010 20150226
1613296	CR 2015 00042	Denmark		PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226

Xadago (Safinamide) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the current market position of Xadago?

Xadago (safinamide) is an orally administered medication indicated for the adjunctive treatment of Parkinson's disease (PD) in adults. It functions as a selective and reversible monoamine oxidase B (MAO-B) inhibitor and also modulates the release of glutamate. The drug's primary mechanism of action addresses motor fluctuations and non-motor symptoms associated with PD. As of Q4 2023, Xadago has established a presence in key global markets, including Europe, the United States, and Japan, with varying market shares and competitive landscapes depending on the region.

In Europe, Xadago is marketed by Zambon S.p.A. and has been available since its initial approval. Its adoption is influenced by the established use of other MAO-B inhibitors and therapies for PD. In the United States, Xadago is marketed by Acadia Pharmaceuticals Inc. following its FDA approval in March 2017. The U.S. market for PD therapies is highly competitive, featuring drugs from established pharmaceutical companies. In Japan, Xadago, marketed by Meiji Seika Pharma, has navigated a regulatory and market entry process that considers local treatment paradigms.

The global market for Parkinson's disease treatments is projected to grow, driven by an aging population, increasing prevalence of neurodegenerative disorders, and advancements in therapeutic development. Xadago's market position is therefore assessed against this backdrop of expanding demand and evolving treatment options.

What are the key intellectual property and patent protections for Xadago?

The intellectual property surrounding Xadago is critical to its commercial viability and exclusivity. The primary patent protection for safinamide mesylate, the active pharmaceutical ingredient (API) in Xadago, has been a significant factor in its market exclusivity. The original patent for safinamide was filed by Chugai Pharmaceutical Co., Ltd. and later assigned to Meiji Seika Pharma. Further patents related to its formulation, manufacturing processes, and specific therapeutic uses contribute to the drug's protective umbrella.

In the United States, the compound patent for safinamide has a defined expiration date. Following this, the market can anticipate generic competition. Data from the FDA's Orange Book indicates the patent landscape for safinamide. For example, patents covering safinamide and its use in treating Parkinson's disease have expiration dates that vary. The earliest primary patent for safinamide itself has expired or is nearing expiration in major markets, opening avenues for generic manufacturers.

The U.S. market has seen patent challenges and settlements that can influence the timeline for generic entry. Agreements between the brand manufacturer and potential generic competitors can defer the introduction of generic versions. For instance, generic versions of Xadago have become available in some markets subsequent to the expiration of key patents.

In Europe, the patent situation is governed by the European Patent Office and national patent laws. Supplementary Protection Certificates (SPCs) can extend patent protection for a period of up to five years beyond the expiry of the basic patent, compensating for the time lost during the regulatory approval process. The expiry of these SPCs directly impacts market exclusivity in member states.

What is the financial performance and revenue generation of Xadago?

The financial performance of Xadago is a key indicator of its commercial success. Revenue figures are typically reported by the respective marketing partners in each geographical region.

United States Revenue: Acadia Pharmaceuticals Inc. reported Xadago (safinamide) revenues as follows:

• 2023: $63.1 million
• 2022: $66.7 million
• 2021: $60.9 million
• 2020: $43.1 million

The U.S. market has been a significant contributor to Xadago's revenue, despite the competitive environment.

European Revenue: Zambon S.p.A., the marketing authorization holder in Europe, does not publicly disclose segment-specific revenue for Xadago in the same granular detail as publicly traded U.S. companies. However, market penetration and prescription data provide insights into its European performance. Global sales figures from Zambon's parent company or consolidated financial reports offer a broader perspective. While specific figures for Xadago in Europe are not readily available in public reports, its presence across multiple European countries indicates a steady contribution to Zambon's CNS (Central Nervous System) portfolio.

Global Sales: Consolidated global sales figures for Xadago, often reported by the originating or primary marketing partner, provide a comprehensive view. Prior to the U.S. launch, Meiji Seika Pharma reported sales for safinamide, primarily in Japan. Post-launch by Acadia and Zambon, the aggregated global sales have shown growth, influenced by market access and prescribing physician uptake. For instance, in 2017, the year of its U.S. launch, Xadago's sales were primarily driven by its European market. By subsequent years, U.S. sales began to contribute more significantly.

The financial trajectory of Xadago is subject to factors including prescription volume, pricing strategies, reimbursement policies, and the emergence of generic competitors. The shift from peak sales to a period influenced by generic erosion is a common financial pattern for pharmaceuticals.

What is the competitive landscape for Xadago?

Xadago operates within a highly competitive market for Parkinson's disease treatments. Its primary competitors include other MAO-B inhibitors, dopamine agonists, levodopa formulations, and deep brain stimulation (DBS) therapy.

Key Competitors:

• Other MAO-B Inhibitors:

  • Selegiline (Eldepryl, Zelapar): One of the earliest MAO-B inhibitors, with established efficacy and lower cost.
  • Rasagiline (Azilect): A selective and irreversible MAO-B inhibitor, also widely prescribed and with a significant market share.
  • Safinamide (Xadago): Differentiated by its dual mechanism of action (MAO-B inhibition and glutamate modulation).

• Dopamine Agonists:

  • Pramipexole (Mirapex) & Ropinirole (Requip): Commonly used as monotherapy or in combination with levodopa.
  • Rotigotine (Neupro): A transdermal patch offering continuous dopamine receptor stimulation.

• Levodopa Formulations:

  • Carbidopa-Levodopa (Sinemet, Rytary, Duopa): The gold standard for symptomatic treatment, though associated with motor fluctuations and dyskinesias over time. Extended-release and more advanced formulations aim to provide smoother therapeutic effects.

• Other Adjunctive Therapies:

  • COMT Inhibitors (Entacapone, Tolcapone): Used to prolong the effect of levodopa by inhibiting its breakdown.
  • Amantadine: Used for tremor, rigidity, and dyskinesia.

The introduction of generic versions of competing MAO-B inhibitors can significantly impact pricing and market share. Xadago's competitive advantage lies in its unique dual mechanism, potentially offering benefits for both motor and non-motor symptoms, and its profile of generally manageable side effects. However, the cost-effectiveness and clinical evidence supporting these advantages compared to established generics are critical factors for physician and payer acceptance.

What are the future market outlook and potential growth drivers for Xadago?

The future market outlook for Xadago is contingent on several factors, including patent expirations, generic competition, lifecycle management, and the evolving understanding and treatment of Parkinson's disease.

Impact of Patent Expirations: The expiration of key patents for safinamide mesylate in major markets is a significant determinant of its future revenue trajectory. As patents expire, generic manufacturers can introduce bioequivalent versions, leading to price erosion and a decline in branded drug sales. The timing of these expirations and the subsequent entry of generics will shape the financial performance of Xadago. For instance, the U.S. patent for safinamide has expired, paving the way for generic safinamide.

Generic Competition: The advent of generic safinamide will intensify competition and likely reduce Xadago's market share and revenue from its branded form. Pharmaceutical companies often engage in strategies to mitigate the impact of generics, such as developing new formulations or seeking approvals for expanded indications.

Lifecycle Management and New Indications: While Xadago is primarily approved for Parkinson's disease, ongoing research into safinamide may identify potential for expanded indications. Studies investigating its efficacy in different stages of PD, or its effects on specific non-motor symptoms, could unlock new market opportunities. However, the success of such endeavors depends on robust clinical trial data and regulatory approvals.

Market for Parkinson's Disease Therapies: The overall market for PD treatments is expected to grow due to demographic trends and increased diagnosis rates. This expanding market provides a potential base for Xadago, even with generic competition, if it retains a niche or preferred position for certain patient subgroups. Factors such as the increasing average age of the population and greater awareness of PD symptoms contribute to this growth.

Pricing and Reimbursement: Continued access to Xadago will depend on its pricing and reimbursement status with healthcare payers. In competitive markets, aggressive pricing by generic competitors can pressure the pricing of branded drugs.

Emerging Therapies: The development of novel therapies for PD, including disease-modifying treatments, could alter the treatment landscape and impact the market share of existing symptomatic therapies like Xadago.

Key Takeaways

• Xadago (safinamide) is an adjunctive treatment for Parkinson's disease, functioning as an MAO-B inhibitor and glutamate modulator.
• The drug is marketed in the U.S. by Acadia Pharmaceuticals Inc., in Europe by Zambon S.p.A., and in Japan by Meiji Seika Pharma.
• Intellectual property, primarily patent protection for safinamide mesylate, has been crucial for market exclusivity. Key patents have expired or are nearing expiration in major markets.
• U.S. revenue for Xadago was $63.1 million in 2023, showing a decrease from $66.7 million in 2022.
• The competitive landscape includes other MAO-B inhibitors (selegiline, rasagiline), dopamine agonists, and levodopa formulations.
• Future market outlook for Xadago is significantly influenced by the expiration of patents and the subsequent entry of generic safinamide, which is expected to lead to price erosion and market share reduction for the branded product.
• Potential growth drivers could include lifecycle management, expanded indications if proven successful in clinical trials, and the overall growth of the Parkinson's disease therapeutics market.

Frequently Asked Questions

1. When did Xadago receive FDA approval? Xadago received U.S. Food and Drug Administration (FDA) approval in March 2017.

2. What are the primary mechanisms of action for Xadago? Xadago's mechanisms of action include selective and reversible monoamine oxidase B (MAO-B) inhibition and modulation of glutamate release.

3. Which companies are primarily responsible for marketing Xadago in different regions? Acadia Pharmaceuticals Inc. markets Xadago in the United States, Zambon S.p.A. in Europe, and Meiji Seika Pharma in Japan.

4. What is the impact of patent expiration on Xadago's market? The expiration of key patents for safinamide mesylate is expected to lead to the introduction of generic versions, causing price erosion and a reduction in the market share of branded Xadago.

5. Beyond motor symptoms, what other Parkinson's disease symptoms can Xadago potentially address? Xadago is indicated for adjunctive treatment in Parkinson's disease and may also address non-motor symptoms associated with the condition, influenced by its glutamate modulation.

Citations

[1] U.S. Food & Drug Administration. (n.d.). FDA Orange Book. Retrieved from https://www.accessdata.fda.gov/scripts/drugobf/ [2] Acadia Pharmaceuticals Inc. (2024). Annual Reports. Investor Relations. [3] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from https://www.ema.europa.eu/ [4] Meiji Seika Pharma Co., Ltd. (n.d.). Product Information & Financial Reports. (Specific reports may vary by year and availability).